Tandem Auto-Allo Transplant for Lymphoma

Phase 2 Completed 42 enrolled Massachusetts General Hospital Dana-Farber Cancer Institute · collab

NaSingle-groupOpen-labelTreatment

Summary

Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in an attempt to induce a graft versus lymphoma effect. This study will assess the feasibility, safety and efficacy of the combination of autologous stem cell transplantation followed by non-myeloablative transplantation for patients with poor-risk aggressive lymphoma.

Timeline

Start: 2010-08
Primary completion: 2014-02
Completion: 2016-02

Publications

Results Chen YB, Li S, Fisher DC, Driscoll J, Del Rio C, Abramson J, Armand P, Barnes J, Brown J, Cutler C, El-Jawahri A, Ho VT, Hochberg E, McAfee S, Takvorian R, Spitzer TR, Antin JH, Soiffer R, Jacobsen E. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant. 2015 Sep;21(9):1583-8. doi: 10.1016/j.bbmt.2015.05.016. Epub 2015 May 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	15 mg/kg	Intravenous
Background	Busulfan	Small molecule	0.8 mg/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	60 mg/kg	Intravenous
Background	Etoposide	Small molecule	30 mg/kg	Intravenous
Background	Fludarabine	Small molecule	30 mg/m2	Intravenous
Background	Methotrexate	Small molecule	5 mg/m2	Intravenous
Background	Sirolimus	Small molecule	4 mg	Oral
Background	Tacrolimus	Small molecule	0.05 mg/kg	Oral
Background	filgrastim	Protein / enzyme biologic	5 ug/kg	Subcutaneous

Tandem Auto-Allo Transplant for Lymphoma

Summary

Timeline

Publications

Drugs

Indications